# Otologic Pharmaceutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/otologic-pharmaceutics

- Industry: Pharmaceuticals
- Headquarters: Oklahoma City, US
- Website: www.otologicpharmaceutics.com
- Total disclosed funding: $4.1M
- Latest round: Series A (Apr 3, 2014)
- Investors on record: 3

## About

Otologic Pharmaceutics, Inc. is a pharmaceutical company focused on innovative solutions for ear-related conditions, enhancing patient outcomes through advanced delivery systems targeting auditory health issues.Founded in 2014 and headquartered in Oklahoma City, US, Otologic Pharmaceutics specializes in developing pharmaceutical solutions for otological conditions. The company raised USD 4.1 million in Series A funding in April 2014, co-led by Accele Biopharma and i2E Inc., with participation from the Oklahoma Life Science Fund. The funding has supported its initiatives to create effective treatments for auditory disorders.Otologic Pharmaceutics specializes in developing innovative pharmaceutical solutions specifically targeting ear-related conditions. The company’s primary offerings include advanced formulations for the treatment of otological diseases, focusing on enhancing patient outcomes through targeted delivery systems. Their solutions cater to healthcare providers, including hospitals and specialized clinics, addressing issues such as ear infections and hearing loss, primarily in North America and Europe.Otologic Pharmaceutics generates revenue through direct sales of its pharmaceutical products to healthcare institutions and pharmacies, establishing a structured B2B transaction model. The company's flagship products include patented formulations sold on a per-unit basis to hospitals and clinics, with pricing aligned with industry standards to reflect the specialized nature of pharmaceutical supplies.In April 2014, Otologic Pharmaceutics, Inc. raised USD 4.1 million in Series A financing, which will support the company's growth strategy. The funding is intended to facilitate the development of new products targeting unmet medical needs in auditory health. Furthermore, Otologic Pharmaceutics aims to expand its market presence in Europe and North America by the end of 2024, working to establish partnerships with additional healthcare providers to increase product accessibility.

## Funding rounds

- Series A, Apr 3, 2014, $4.1M — Oklahoma Life Science Fund, i2E Inc., Accele Biopharma

## Investors

- Oklahoma Life Science Fund (https://capitalatlas.ai/funds/oklahoma-life-science-fund) — Series A
- i2E Inc. — Series A
- Accele Biopharma (https://capitalatlas.ai/funds/accele-biopharma) — Series A